EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences. “2021 represents a ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis "This Phase 2 trial of IMO-8400 will enable us to evaluate over a 12-week ...
A preclinical psoriasis publication sends Idera soaring. Should shareholders latch onto this third-party news or use it as an opportunity to take their profits? Although we don't believe in timing the ...
Shares of Idera Pharmaceuticals (NASDAQ: IDRA) are down around 15% year to date. And that's a good thing, relatively speaking: The clinical-stage biotech's stock was down by more than 55% just a few ...
HOUSTON—May 23, 2019—Idera, Inc. (“Idera” or “the Company”), parent company of global B2B software productivity brands, today announced it will receive a new minority investment from Partners Group, a ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to ...
Cambridge, Mass.-based Idera Pharmaceuticals and Bermuda-based Vivelix Pharmaceuticals entered into an exclusive license and collaboration agreement giving Vivelix the rights to develop and market IMO ...
The clinical stage biopharma said that it is selling 25 million shares of common stock for $2.00 each. In addition, the company also granted the underwriters of the deal the option to purchase an ...
New AI capabilities help DBAs move from performance visibility to performance resolution—turning slow queries into actionable index recommendations in minutes HOUSTON, March 19, 2026 /PRNewswire/ -- ...
Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis "This Phase 2 trial of IMO-8400 will enable us to evaluate over a 12-week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results